[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Horus University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":193},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,70,90,112,144,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053683","high-intensity-interval-training-versus-moderate-intensity-continuous-training-on-gut-microbiota-in-non-alcoholic-fatty-liver-100053683",false,"NCT07697313","High-intensity Interval Training Versus Moderate Intensity Continuous Training on Gut Microbiota in Non-alcoholic Fatty Liver","Inclusion Criteria:\n\n1. Patients from both genders aged 40 - 60 years old diagnosed with Non-alcoholic Fatty Liver disease by ultrasonography.\n2. Body mass index will range from 30 to 34.9 kg\u002Fm².\n3. Patients with central obesity (waist circumference 90 cm for men and 85 cm for women).\n4. Patients who have taken no regular exercise in the last year (\\\u003C3 times\u002Fweek and 30 min\u002Ftime.\n5. No antibiotic or probiotic use for at least last 3 months.\n6. Medical drugs such as metformin, sulfonylureas, statins, and blood pressure medication were eligible, as well as stable.\n\nExclusion Criteria:\n\n1. History of liver cirrhosis or other chronic liver diseases.\n2. Use of medications affecting gut microbiota (e.g., laxatives, metformin, proton pump inhibitors).\n3. Recent gastrointestinal infections or surgeries.\n4. Diabetes Mellitus type 1 or uncontrolled type 2.\n5. Cardiovascular, respiratory, or musculoskeletal disorders limiting exercise capacity.\n6. Active smokers.\n7. Pregnancy or breastfeeding.\n8. Uncontrolled hypertension.\n9. Communication disorders.\n10. Bleeding disorders.","ALL","40 Years","60 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","To compare High-Intensity Interval Training versus moderate intensity continuous training on gut microbiota in Non- Alcoholic Fatty Liver.",[26],"Non-alcoholic Fatty Liver","NOT_YET_RECRUITING","2026-07-05",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-07-10",{"date":35,"type":20},"2026-10-10",{"name":37,"class":38},"Horus University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":17,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":39},"100643569","phase-2-desloratadine-as-adjunct-therapy-for-rheumatoid-arthritis-100643569","NCT07632872","Desloratadine as Adjunct Therapy for Rheumatoid Arthritis","Effect of Desloratadine as Add-On Therapy in Rheumatoid Arthritis","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria.\n* Disease Activity Score in 28 joints (DAS28) greater than 2.6.\n* Age between 18 and 60 years.\n* Male and female patients.\n* Patients receiving methotrexate in addition to standard conventional therapy.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with renal or hepatic disease.\n* Known hypersensitivity to the study medications.\n* Current use of antioxidant supplements.\n* History of psychiatric disorders.\n* Use of oral prednisolone at a dose greater than 15 mg per day.\n* Current treatment with biological disease modifying antirheumatic drugs.\n* Pregnant or breastfeeding patients.\n* History of cardiac arrhythmias or prolonged QT interval.\n* Use of medications known to prolong the QT interval.","18 Years",{"count":19,"type":20},[50],"PHASE2","Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease.\n\nThe purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment.\n\nThe study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.",[53,54],"Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",[56,57,58,59,60],"Desloratadine","Rheumatoid arthritis","Add-on therapy","Inflammation","Randomized controlled trial","RECRUITING","2026-06-02",{"date":64,"type":31},"2026-06-08",{"date":66,"type":31},"2026-05-23",{"date":68,"type":20},"2027-01",{"name":37,"class":38},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":17,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":39},"100643188","phase-2-effect-of-roflumilast-as-add-on-therapy-in-rheumatoid-arthritis-100643188","NCT07632846","Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria.\n* Disease Activity Score in 28 joints (DAS28) greater than 2.6.\n* Age between 18 and 60 years.\n* Male and female patients.\n* Patients receiving methotrexate in addition to standard conventional therapy.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Exclusion Criteria:\n* Patients with renal or hepatic disease.\n* Known hypersensitivity to the study medications.\n* Current use of antioxidant supplements.\n* History of psychiatric disorders.\n* Use of oral prednisolone at a dose greater than 15 mg per day.\n* Current treatment with biological disease modifying antirheumatic drugs.\n* Pregnant or breastfeeding patients.\n* History of cardiac arrhythmias or prolonged QT interval.\n* Use of medications known to prolong the QT interval",{"count":77,"type":20},50,[50],"Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease.\n\nThe purpose of this study is to evaluate the effectiveness and safety of adding roflumilast to standard therapy in patients with active rheumatoid arthritis. Participants will receive either roflumilast or placebo in addition to their usual treatment.\n\nThe study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether roflumilast could be a useful add-on treatment option for patients with rheumatoid arthritis.",[54,53],[82,57,60,83,58],"Roflumilast","Phosphodiesterase-4 inhibitor",{"date":64,"type":31},{"date":86,"type":31},"2026-05-19",{"date":88,"type":20},"2026-12",{"name":37,"class":38},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":17,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":39},"100636489","phase-2-effect-of-roflumilast-and-desloratadine-as-add-on-therapy-in-patients-with-rheumatoid-arthritis-100636489","NCT07566351","Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis","Clinical Study to Compare the Possible Efficacy and Safety of Roflumilast and Desloratadine as Adjuvant Therapy for Rheumatoid Arthritis","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria.\n* Disease activity score in 28 joints (DAS28) greater than 2.6.\n* Age between 18 and 60 years.\n* Male and female patients.\n* Patients receiving methotrexate in addition to standard conventional therapy.\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Patients with renal or hepatic disease.\n* Known hypersensitivity to the study medications.\n* Current use of antioxidant supplements.\n* History of psychiatric disorders.\n* Use of oral prednisolone at a dose greater than 15 mg per day.\n* Current treatment with biological disease modifying antirheumatic drugs.\n* Pregnant or breastfeeding patients.\n* History of cardiac arrhythmias or prolonged QT interval.\n* Use of medications known to prolong the QT interval.",{"count":98,"type":20},90,[50],"Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and disability. Although standard disease-modifying antirheumatic drugs (DMARDs) are effective for many patients, some individuals continue to experience active disease and inflammation. The aim of this study is to evaluate the effectiveness and safety of adding either roflumilast or desloratadine to standard DMARD therapy in patients with rheumatoid arthritis. Participants will be randomly assigned to receive either roflumilast, desloratadine, or placebo in addition to their usual treatment. The study will assess changes in disease activity, inflammatory biomarkers, and patient-reported outcomes over a three-month follow-up period. The results of this study may help identify new add-on treatment options to improve disease control in patients with rheumatoid arthritis.",[54],[57,82,56,58,103],"double blind Randomized controlled trial","2026-05-08",{"date":106,"type":31},"2026-05-12",{"date":108,"type":31},"2026-04-23",{"date":110,"type":20},"2027-07",{"name":37,"class":38},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":15,"minAge":47,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":39},"100598729","liquid-phase-concentrated-growth-factor-versus-conventional-arthrocentesis-in-temporomandibular-disc-displacement-100598729","NCT07075276","Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Temporomandibular Disc Displacement","Injection of Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Management of Temporomandibular Disc Displacement: A Randomized Controlled Clinical Trial","LPCGF in TMDs","Inclusion Criteria:\n\n* 1\\. Adults aged 18-45 years. 2. Patients scored as (ASA I).9 3. Presence of complete or nearly complete set of natural dentition with Angle class I occlusion. 4. Diagnosed with unilateral involvement of disc displacement, according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC\u002FTMD).10 5. Symptoms include one or more of the following: pain, joint sounds, and limited mandibular movement (Maximum Mouth Opening\\\u003C 40mm) 6. No prior surgical intervention for TMD. 7. Patient's willingness to participate and follow the study protocol.\n\nExclusion Criteria:\n\n* 1\\. TMJ pathology related to mechanical deformities 2. Psychiatric problems or presence of systemic diseases that may affect healing (e.g., uncontrolled diabetes, autoimmune disorders, hematologic or neurologic disorders, inflammatory or connective tissue disorders as well as rheumatological or previous infectious diseases, head and neck cancer). 3. Patient unwilling or has contraindication to MRI 4. Previous injections or surgical interventions of the TMJ. 5. Concurrent use of anticoagulants or anti-inflammatory medications within the last 30 days. 6. Pregnant or breastfeeding women. 7. History of trauma or infection in the TMJ region. 8. Allergy to local anesthetics or other components used in the study. 9. Patients diagnosed with (Disc Displacement with reduction with no pain or limited mandibular movements).",true,"45 Years",{"count":123,"type":20},32,[23],"This study aims to rigorously assess the effectiveness of LPCGF in the management of internal disc displacement in patients with TMD through a randomized clinical trial. By comparing LPCGF therapy with conventional arthrocentesis, this research looks to provide robust evidence on the efficacy, safety, and potential role of (LPCGF) as an alternative therapeutic choice for IDD.",[127,128,129],"Temporomandibular Disorders (TMD)","Internal Derangement of the Tempromandibular Joint","Anterior Disc Displacement",[131,132,133,134,135],"Temporomandibular disorder","Concentrated growth factor","Anterior disc displacement with reduction","Anterior disc displacement without reduction","Arthrocentesis","2026-03-08",{"date":138,"type":31},"2026-03-11",{"date":140,"type":31},"2025-10-01",{"date":142,"type":20},"2026-06-01",{"name":37,"class":38},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":120,"sex":15,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":39},"100551229","demineralized-dentin-allograft-versus-demineralized-dentin-autograft-for-socket-preservation-100551229","NCT06457373","Demineralized Dentin Allograft Versus Demineralized Dentin Autograft for Socket Preservation","The Demineralized Dentin Allograft Versus Demineralized Dentin Autograft for Socket Preservation After Surgical Extraction of Impacted Mandibular Third Molar","Inclusion Criteria:\n\n1. Patients aged between 25 to 35 years old.\n2. Patients scored as (ASA I).\n3. No adverse habits such as smoking, tobacco chewing, alcohol.\n4. Patients having bilaterally impacted mandibular third molar with similar degree of difficulty according to (Kim JY, et al).\n5. The recipient alveolar sockets are free of any pre-existing periapical pathology, based on x-ray.\n6. Alveolar sockets with a depth of 5 mm or more, using periodontal probe for assessment.\n7. Patients sign a consent for all procedures.\n\nExclusion Criteria:\n\n* 1\\) Pregnant or lactating patients. 2) Relevant systemic diseases. 3) Patients with history of chemotherapy or radiotherapy.","25 Years","35 Years",{"count":154,"type":20},40,[23],"This study is designed to evaluate and compare clinically and radiographically the effectiveness of Demineralized Dentin Allograft (DDA) versus Demineralized Dentin Autograft (Auto-DD) for preservation of alveolar ridge dimensions after surgical extraction of the impacted mandibular third molar.",[158],"Alveolar Bone Loss",[160,161,162],"Socket preservation","Impacted mandibular third molar","Alveolar ridge Augmentation",{"date":138,"type":31},{"date":165,"type":20},"2026-07-01",{"date":167,"type":20},"2027-07-30",{"name":37,"class":38},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":176,"maxAge":47,"enrollmentInfo":177,"targetDuration":4,"studyType":179,"phases":4,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":39},"100554286","validity-and-reliability-of-the-egyptian-arabic-version-of-abilhand-kids-100554286","NCT06497114","Validity and Reliability of the Egyptian-Arabic Version of ABILHAND-Kids","Validity and Reliability of the Egyptian-Arabic Version of ABILHAND-Kids in a Sample of Egyptian Children With Cerebral Palsy.","Inclusion Criteria:\n\n\\- Parents of 100 children with CP will be recruited.\n\nExclusion Criteria:\n\n* mental retardation","4 Years",{"count":178,"type":20},100,"OBSERVATIONAL","HYPOTHESES It is hypothesized that the Egyptian-Arabic ABILHAND-Kids 21-item will be psychometrically appropriate to be used with Egyptian children with cerebral palsy.",[182],"Cerebral Palsy",[184],"hand function","2024-07-04",{"date":187,"type":31},"2024-07-11",{"date":189,"type":31},"2024-06-01",{"date":191,"type":20},"2024-10-01",{"name":37,"class":38},""]